Thrivent Financial For Lutherans Buys New Holdings in Cutera, Inc. (CUTR)

Thrivent Financial For Lutherans bought a new position in shares of Cutera, Inc. (NASDAQ:CUTR) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 8,780 shares of the medical device company’s stock, valued at approximately $398,000. Thrivent Financial For Lutherans owned 0.06% of Cutera as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the stock. Renaissance Technologies LLC grew its holdings in Cutera by 3.6% during the fourth quarter. Renaissance Technologies LLC now owns 1,083,600 shares of the medical device company’s stock worth $49,141,000 after acquiring an additional 37,920 shares during the period. Koch Industries Inc. grew its holdings in Cutera by 165.5% during the fourth quarter. Koch Industries Inc. now owns 14,657 shares of the medical device company’s stock worth $665,000 after acquiring an additional 9,136 shares during the period. AXA purchased a new position in Cutera in the 4th quarter worth about $254,000. Alliancebernstein L.P. increased its stake in Cutera by 25.2% in the 4th quarter. Alliancebernstein L.P. now owns 32,800 shares of the medical device company’s stock worth $1,487,000 after purchasing an additional 6,600 shares in the last quarter. Finally, Bogle Investment Management L P DE increased its stake in Cutera by 77.2% in the 4th quarter. Bogle Investment Management L P DE now owns 185,174 shares of the medical device company’s stock worth $8,397,000 after purchasing an additional 80,700 shares in the last quarter. 95.29% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

Cutera, Inc. (NASDAQ CUTR) opened at $51.95 on Monday. Cutera, Inc. has a 12 month low of $18.50 and a 12 month high of $55.00. The firm has a market capitalization of $719.77, a PE ratio of 68.36, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51.

Cutera (NASDAQ:CUTR) last released its earnings results on Wednesday, February 14th. The medical device company reported $0.42 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.33 by $0.09. Cutera had a return on equity of 18.31% and a net margin of 19.80%. The company had revenue of $47.60 million for the quarter, compared to analysts’ expectations of $43.96 million. During the same quarter in the previous year, the business posted $0.30 EPS. The business’s revenue for the quarter was up 25.6% on a year-over-year basis. sell-side analysts predict that Cutera, Inc. will post 1.1 earnings per share for the current year.

In other Cutera news, insider James A. Reinstein sold 7,175 shares of Cutera stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $45.35, for a total transaction of $325,386.25. Following the transaction, the insider now owns 132,284 shares of the company’s stock, valued at approximately $5,999,079.40. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Larry Laber sold 5,843 shares of Cutera stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $45.35, for a total value of $264,980.05. Following the transaction, the executive vice president now directly owns 79,463 shares in the company, valued at approximately $3,603,647.05. The disclosure for this sale can be found here. Insiders own 3.30% of the company’s stock.

A number of brokerages recently weighed in on CUTR. BidaskClub raised Cutera from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 15th. Zacks Investment Research cut Cutera from a “hold” rating to a “sell” rating in a research note on Monday, January 1st. Gabelli reissued a “buy” rating on shares of Cutera in a research note on Friday, February 16th. Finally, Stephens began coverage on Cutera in a research note on Tuesday, March 13th. They issued an “overweight” rating and a $60.00 price target on the stock. One investment analyst has rated the stock with a hold rating, four have given a buy rating and two have assigned a strong buy rating to the company’s stock. Cutera presently has a consensus rating of “Buy” and an average price target of $45.00.

ILLEGAL ACTIVITY WARNING: This report was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3302251/thrivent-financial-for-lutherans-buys-new-holdings-in-cutera-inc-cutr.html.

Cutera Company Profile

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

Institutional Ownership by Quarter for Cutera (NASDAQ:CUTR)

Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

SunPower  Raised to “Buy” at BidaskClub
SunPower Raised to “Buy” at BidaskClub
FY2018 Earnings Estimate for Kinder Morgan Canada Issued By National Bank Financial
FY2018 Earnings Estimate for Kinder Morgan Canada Issued By National Bank Financial
Yintech Investment  Upgraded by BidaskClub to Hold
Yintech Investment Upgraded by BidaskClub to Hold
NICE Systems  Raised to Strong-Buy at Zacks Investment Research
NICE Systems Raised to Strong-Buy at Zacks Investment Research
Scorpio Bulkers  Cut to Sell at Zacks Investment Research
Scorpio Bulkers Cut to Sell at Zacks Investment Research
Zacks Investment Research Upgrades WesBanco  to Hold
Zacks Investment Research Upgrades WesBanco to Hold


© 2006-2018 Ticker Report. Google+.